A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Study identification

NCT ID

NCT06528314

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Akero Therapeutics, Inc

Industry

Enrollment

2,150 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 80 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 3, 2024

Primary completion

Jan 31, 2030

Completion

Feb 28, 2030

Last update posted

Aug 18, 2026

2024 – 2030

United States locations

U.S. sites

165

U.S. states

34

U.S. cities

142

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.